Determination of the Prevalence of Postcovid Syndrome and Assessment of the Effectiveness of the Drug Cortexin in the Treatment of Neurological Disorders in Patients with Postcovid Syndrome. Results of the CORTEX Multicenter Clinical and Epidemiological Observational Program

M V Putilina; Z Yu Mutovina; O V Kurushina; D M Khalilova; E N Saverskaya; S B Stepanova; M A Khoreva; A S Starikov

doi:10.1007/s11055-022-01307-2

Determination of the Prevalence of Postcovid Syndrome and Assessment of the Effectiveness of the Drug Cortexin in the Treatment of Neurological Disorders in Patients with Postcovid Syndrome. Results of the CORTEX Multicenter Clinical and Epidemiological Observational Program

Neurosci Behav Physiol. 2022;52(6):836-841. doi: 10.1007/s11055-022-01307-2. Epub 2022 Oct 26.

Authors

M V Putilina¹, Z Yu Mutovina², O V Kurushina³, D M Khalilova⁴, E N Saverskaya⁵, S B Stepanova⁶, M A Khoreva⁷, A S Starikov⁸

Affiliations

¹ Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia.
² City Clinical Hospital No. 52, Moscow Health Department, Moscow, Russia.
³ Volgograd State Medical University, Russian Ministry of Health, Volgograd, Russia.
⁴ Azerbaijan State Medical University, Baku, Azerbaijan.
⁵ Moscow State University of Food Production, Moscow, Russia.
⁶ South Ural State Medical University, Russian Ministry of Health, Chelyabinsk, Russia.
⁷ Altai State Medical University, Russian Ministry of Health, Barnaul, Russia.
⁸ Pitirim Sorokin Syktyvkar State University, Syktyvkar, Russia.

Abstract

Objectives. To study the prevalence and clinical manifestations of postcovid syndrome (PCS) in out-patients and to assess the efficacy of treatment with the drug Cortexin at doses of 10 and 20 mg i.m. for 10 days. Materials and methods. A total of 979 patients with PCS from regions of the Russian Federation, Azerbaijan, Kyrgyzstan, and Kazakhstan were studied; mean age was 54.6 ± 4.5 years; duration of COVID-19 was from one month upwards. Investigations involved three visits. The first was on the day of consultation (assessment of complaints, analysis of scale indicators, prescription of drug Cortexin at a dose of 10 or 20 mg i.m. for 10 days). The second visit (telephone consultation) was on day 10-14. The third visit was on day 30 of out-patient treatment. Assessment of patients' status used an asthenia assessment scale (MFI-20), a brief mental state assessment scale (MMSE), the Schulte test, and the Subjective Treatment Quality Assessment Scale. Results. The proportion of patients with PCS was up to 30% of all neurological admissions. The commonest manifestations were: fatigue, general weakness, decreased memory and concentration of attention, vertigo, sleep impairment, irritability, and aggression; less frequent were breathlessness, pain, increased sweating, anosmia, hyposmia, dysgeusia, paresthesia, hair loss, degradation of vision, tachycardia, allergic reactions, menstrual cycle impairments, erectile dysfunction, panic attacks, suicidal ideation, depression and refusal to eat meat. Conclusions: No associations were found between clinical symptomatology and the severity of COVID-19, the volume of lung tissue affected, or different periods of postcovid syndrome. Cortexin was found to be effective at doses of 10 and 20 mg for correcting the cognitive and asthenic manifestations of PCS. Cortexin was found to have anti-anxiety, antidepressant, and anxiolytic effects, which were more marked at the 20-mg dose.

Keywords: COVID-19; Cortexin; SARS-CoV-2; cognitive impairment; fatigue; olfactory impairment; postcovid syndrome; prevalence.

© Springer Nature Switzerland AG 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.